GlassScriptPhysician profile
Marivel B Rodriguez
NPI 1649474198
$3,272.83
in general payments reported to CMS, 2019-2025
22 companies · $202 in 2025
The $202 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,075 · 2022: $1,209 · 2023: $488 · 2024: $298 · 2025: $202.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $890 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $889.57 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $614.42 | 2021-2025 | |
| Actelion Pharmaceuticals US, INC. | $493.54 | 2023-2025 | Uptravi, Opsumit |
| Merck Sharp & Dohme LLC | $343.94 | 2021-2023 | Verquvo |
| Amarin Pharma, INC. | $230.91 | 2021-2022 | |
| Esperion Therapeutics, INC. | $230.86 | 2021-2022 | |
| Pfizer INC. | $221.59 | 2021-2023 | |
| Janssen Pharmaceuticals, INC | $166.84 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $164.83 | 2021-2022 | |
| Amgen INC. | $131.60 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $116.79 | 2021-2023 | Farxiga |
| Kiniksa Pharmaceuticals, LTD. | $111.22 | 2022-2023 | Arcalyst |
| Boston Scientific Corporation | $95.57 | 2022-2025 | Farapulse, Varithena Administration Pack |
| Alnylam Pharmaceuticals INC. | $60.94 | 2021-2023 | Amvuttra |
| Kowa Pharmaceuticals America, INC. | $60.46 | 2021-2022 | |
| Biotronik INC. | $47.09 | 2021 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $40.48 | 2021-2022 | |
| Abbott Laboratories | $35.26 | 2022-2024 | Cardiomems |
| Daiichi Sankyo INC. | $29.13 | 2023 | Injectafer |
| Edwards Lifesciences Corporation | $22.85 | 2024 | Sapien 3 Ultra Resilia |
| Gilead Sciences, INC. | $21.16 | 2022 | |
| Althera Pharmaceuticals LLC | $19.17 | 2021 | |
| Surmodics, INC. | $14.18 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marivel Rodriguez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.